Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598905 | 0.84 | CHRNB4 (0.69) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL3591034 | 0.82 | CHRM2 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL3604438 | 0.80 | MAOA (0.46) | — | |
| SCHEMBL3605852 | 0.80 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL1408716 | 0.74 | TLR4 (0.47) | — | |
| SCHEMBL30820761 | 0.74 | CHRNB2 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| Hydrochloric Acid SCHEMBL15819873 | 0.73 | TLR4 (0.46) | — | |
| SCHEMBL20946450 | 0.72 | TLR4 (0.48) | — | |
| SCHEMBL20472615 | 0.72 | PARP15 (0.46) | — | |
| SCHEMBL27697987 | 0.72 | ALDH1A1 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | CHRNB4 217/4885CHRNA3 161/4885CHRNB2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.